Narrative Update • Aug 13

Over the last 7 days, the Biotech industry has remained flat, although notably Biocytogen Pharmaceuticals (Beijing) gained 12%. Unfortunately though, the industry is down 25% over the past 12 months. Earnings are forecast to grow by 33% annually.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 16 Aug 2026 | HK$961.4b | HK$95.3b | -HK$3,965,103,594.15 | 26.1x | -242.5x | 10.1x |
| Tue, 14 Jul 2026 | HK$916.6b | HK$94.4b | -HK$4,117,015,422.35 | 20.3x | -222.6x | 9.7x |
| Thu, 11 Jun 2026 | HK$801.3b | HK$94.6b | -HK$4,476,325,461.73 | 17.4x | -179x | 8.5x |
| Sat, 09 May 2026 | HK$1.0t | HK$94.0b | -HK$3,462,604,676.34 | 23x | -291.1x | 10.7x |
| Mon, 06 Apr 2026 | HK$1.1t | HK$92.6b | -HK$3,975,558,297.75 | 31.7x | -286.3x | 12.3x |
| Wed, 04 Mar 2026 | HK$897.6b | HK$72.2b | -HK$12,324,949,498.10 | 40.8x | -72.8x | 12.4x |
| Fri, 30 Jan 2026 | HK$964.7b | HK$70.3b | -HK$13,986,101,211.05 | 33.7x | -69x | 13.7x |
| Sun, 28 Dec 2025 | HK$955.3b | HK$69.8b | -HK$13,773,740,182.09 | 39.1x | -69.4x | 13.7x |
| Tue, 25 Nov 2025 | HK$1.0t | HK$69.0b | -HK$12,862,606,084.97 | 40.4x | -78.4x | 14.6x |
| Thu, 23 Oct 2025 | HK$1.0t | HK$68.3b | -HK$13,113,789,226.93 | 49.9x | -77.3x | 14.8x |
| Sat, 20 Sep 2025 | HK$1.1t | HK$68.4b | -HK$13,523,295,967.12 | 46.8x | -81.5x | 16.1x |
| Mon, 18 Aug 2025 | HK$1.1t | HK$63.6b | -HK$12,500,118,358.30 | 48.2x | -87.1x | 17.1x |
| Wed, 16 Jul 2025 | HK$832.0b | HK$63.7b | -HK$12,202,930,208.22 | 33.3x | -68.2x | 13.1x |
| Fri, 13 Jun 2025 | HK$754.6b | HK$62.2b | -HK$11,787,564,617.68 | 36x | -64x | 12.1x |
| Sun, 11 May 2025 | HK$562.7b | HK$61.1b | -HK$11,743,365,230.68 | 30.3x | -47.9x | 9.2x |
| Tue, 08 Apr 2025 | HK$431.7b | HK$58.1b | -HK$10,821,715,306.27 | 24.5x | -39.9x | 7.4x |
| Thu, 06 Mar 2025 | HK$449.6b | HK$52.3b | -HK$16,825,648,866.33 | 20.5x | -26.7x | 8.6x |
| Sat, 01 Feb 2025 | HK$357.4b | HK$52.3b | -HK$17,402,481,645.88 | 12.3x | -20.5x | 6.8x |
| Mon, 30 Dec 2024 | HK$376.2b | HK$51.8b | -HK$17,210,526,418.00 | 10.8x | -21.9x | 7.3x |
| Wed, 27 Nov 2024 | HK$398.8b | HK$52.3b | -HK$17,408,113,239.34 | 10.5x | -22.9x | 7.6x |
| Fri, 25 Oct 2024 | HK$399.8b | HK$52.3b | -HK$17,903,258,098.12 | 11.8x | -22.3x | 7.6x |
| Sun, 22 Sep 2024 | HK$356.5b | HK$52.9b | -HK$18,365,265,896.23 | 10.8x | -19.4x | 6.7x |
| Tue, 20 Aug 2024 | HK$321.3b | HK$51.4b | -HK$19,189,409,133.62 | 10.1x | -16.7x | 6.2x |
| Thu, 18 Jul 2024 | HK$329.4b | HK$49.7b | -HK$19,463,659,945.98 | 12.6x | -16.9x | 6.6x |
| Sat, 15 Jun 2024 | HK$339.0b | HK$49.7b | -HK$19,479,313,074.00 | 10.5x | -17.4x | 6.8x |
| Mon, 13 May 2024 | HK$381.6b | HK$49.9b | -HK$19,280,058,128.71 | 12.4x | -19.8x | 7.6x |
| Wed, 10 Apr 2024 | HK$348.5b | HK$49.3b | -HK$19,515,680,148.97 | 11x | -17.9x | 7.1x |
| Fri, 08 Mar 2024 | HK$335.4b | HK$47.2b | -HK$20,389,266,599.64 | 15.3x | -16.4x | 7.1x |
| Sun, 04 Feb 2024 | HK$298.0b | HK$46.8b | -HK$20,180,773,943.00 | 15x | -14.8x | 6.4x |
| Tue, 02 Jan 2024 | HK$409.5b | HK$47.3b | -HK$20,423,453,967.00 | 17.7x | -20.1x | 8.7x |
| Thu, 30 Nov 2023 | HK$408.3b | HK$46.5b | -HK$18,752,881,282.00 | 19x | -21.8x | 8.8x |
| Sat, 28 Oct 2023 | HK$397.2b | HK$44.9b | -HK$19,035,005,211.00 | 13.4x | -20.9x | 8.8x |
| Mon, 25 Sep 2023 | HK$413.2b | HK$44.9b | -HK$18,918,406,180.00 | 16.5x | -21.8x | 9.2x |
| Wed, 23 Aug 2023 | HK$370.9b | HK$35.9b | -HK$22,907,163,046.00 | 14.7x | -16.2x | 10.3x |
-16.2x
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -1.30% | |
| Healthcare | -0.32% | |
| Biotech | -0.26% | |
| Biotech | -0.26% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2315 Biocytogen Pharmaceuticals (Beijing) | HK$69.00 | 11.7% +HK$3.2b | 180.0% | PE91.2x | |
| 9887 Nanjing Leads Biolabs | HK$73.30 | 14.0% +HK$1.8b | 5.7% | PS70.7x | |
| 6915 Jiangxi Institute of Biological Products | HK$14.00 | 45.4% +HK$1.3b | n/a | PE39.1x | |
| 7666 Metis TechBio | HK$12.11 | 8.9% +HK$1.2b | n/a | PS117.2x | |
| 9969 InnoCare Pharma | HK$14.94 | 4.5% +HK$1.1b | -23.8% | PE29.8x |